High-dose chemotherapy improves outcomes for multiply relapsed and refractory germ-cell tumors
Testicular cancer is the most common malignancy in young men ages 15 to 35. Most patients respond well to cisplatin-based chemotherapy, with cure rates for metastatic disease as high as 70-80%, but some patients have tumors that relapse. High-dose chemotherapy (HDC) can be effective for some patients after an initial relapse, but outcomes are poor for those with multiple relapses or refractory tumors. In a Phase II trial, researchers...
Triple combination therapy shows promise for treatment-resistant microsatellite stable BRAF V600E-mutant metastatic colorectal cancer
The BRAF V600E gene mutation makes colorectal cancers (CRCs) more aggressive, leading to poorer survival rates. While some CRCs with high...
Fluorescent tracer helps identify precancerous lesions in pancreatic cancer models
During surgical treatment for pancreatic cancer, pre-malignant pancreatic lesions ¨C which can develop into pancreatic cancer ¨C often go unnoticed...
Large-scale CRISPR screening in stomach organoids reveals gene-drug interactions
Scientists often use organoids ¨C?laboratory-grown human cell culture systems?that closely mimic body organs ¨C to?gain deeper insights into cancer biology and understand how tumors respond to drugs. Researchers led by?Yuan-Hung Lo, Ph.D., used organoids along with several CRISPR? gene editing tools to study how cisplatin?chemotherapy?interacts with different genes in the human stomach.?The screens...
Final trial data from ELI-002 cancer immunotherapy vaccine reinforce promising results
In initial results from the AMPLIFY-201 trial, co-led by Shubham Pant, M.D., an immunotherapy vaccine targeting the lymph nodes showed potential...
Targeting brain-liver pathway with electronic wearables could prevent cancer-associated weight and muscle loss
Many patients with cancer develop a serious and currently incurable condition called cachexia, which is characterized by rapid weight and...
Novel drug confirms NSD2 protein as therapeutic target in lung and pancreatic cancers
Studies have shown that the NSD2 protein fuels cancer growth, particularly in difficult-to-treat cancers with KRAS mutations, suggesting it...
MDS subtype associated with poor outcomes after venetoclax-based therapy
Myelodysplastic syndromes?(MDS) are a group of diseases in which the bone marrow does not produce enough healthy blood cells. The erythroid...
New biomarker and strategy identify and overcome resistance in HR+/HER2- breast cancer
CDK4/6 inhibitors are targeted therapies commonly used as first-line treatments for patients with hormone receptor-positive HER2-negative...
Study provides insights into advanced ovarian cancer tumors after treatment
Many patients with advanced ovarian cancer treated with frontline therapies still end up with clinically undetectable amounts of cancer cells...